2022 Savings Offer for AJOVY is here. Learn more
Efficacy for AJOVY

Sustained efficacy1 with no evidence of “wearing off”2

Patients experienced significantly more migraine-free days with AJOVY vs placebo in the HALO + Long-Term Extension Studies1,3-5

See Study Design

Episodic Migraine

Consider limitations of Long-Term Extension study design when interpreting efficacy results.

Patients randomized to monthly dosing had a mean baseline of 8.9 migraine days per month and experienced, on average1:
4.3 fewer migraine days at month 3 vs 3.1 with placebo (P<0.001).1,3

Patients randomized to quarterly dosing had a mean baseline of 9.2 migraine days per month and experienced, on average1:
4.2 fewer migraine days at month 3 vs 3.1 with placebo (P<0.001).1,3

*Mean baseline of 8.9 migraine days per month with monthly dosing.1
Reduction in monthly average number of migraine days from the Long-Term Extension study was 5.1 with monthly dosing.3

No evidence of “wearing off” with AJOVY was
observed from one dose to the next2

POST HOC WEEKS 1-3 VS 4

Mean number of weekly migraine days during weeks 1-3
vs week 4 at months 3, 6, 9, and 15 with monthly dosing2‡

Generated with Avocode.Group 2719Rectangle 870 copy 2Path 2273Group 2465Rectangle 870 copyPath 2271Path 2272Rectangle 537Rectangle 537Group 2722Rectangle 517 copy 4Rectangle 517 copy 6Path 2256Path 2257Rectangle 534Rectangle 534 copy 2Path 2260Path 2261Rectangle 534Rectangle 534 copy 2Path 2262Path 2268Rectangle 534Rectangle 534 copy 2Path 2269Path 2274Rectangle 534Rectangle 534 copy 2Path 2275Path 2277Path 2263Path 2270Path 2264Path 2276Rectangle 517 copyRectangle 517 copy 2Rectangle 517 copy 3Rectangle 517 copy 5Path 2258Path 2259Path 2265Path 2266Path 2267linesPath 2551

POST HOC WEEKS 1-2 VS 11-12

Mean number of weekly migraine days in weeks 1-2
vs weeks 11-12 with quarterly dosing2‡

Generated with Avocode.Group 2720Rectangle 870 copy 2Path 2310Group 2459Rectangle 870 copyPath 2308Path 2309Rectangle 537Rectangle 537Group 2721Rectangle 534Rectangle 534 copyPath 2296Path 2297Rectangle 534Rectangle 534 copyPath 2298Path 2311linesPath 2299Path 2300Rectangle 517 copyRectangle 517 copy 2Rectangle 517 copy 3Rectangle 517 copy 4Rectangle 517 copy 6Rectangle 517 copy 5Path 2301Path 2302Path 2303Path 2304Path 2305Path 2306Path 2307Path 2549

For all post hoc analyses, no determination of statistical significance can be made and no conclusions should be drawn.

Study design: Of the patients who rolled over from the HALO studies, 611 from the HALO CM study (monthly, n=305; quarterly, n=306) and 432 from the HALO EM study (monthly, n=215; quarterly, n=217) had received AJOVY injection during the respective HALO study and were included in post hoc analyses during the long-term, open-label extension study2

In clinical trials, AJOVY reduced migraine days by 50% or more for some patients1

EPISODIC MIGRAINE

Secondary endpoint

Reduction

in monthly number of migraine days with monthly dosing

47.7% vs 27.9%

with placebo
(P<0.001)1

Exploratory analyses

Reduction

in monthly number of migraine days with monthly dosing

27.1% vs 15.4%

with placebo
(Exploratory analysis)3

Exploratory analyses

Reduction

in monthly number of migraine days with monthly dosing

10.1% vs 4.5%

with placebo
(Exploratory analysis)3

For all exploratory analyses, no determination of statistical significance can be made and no conclusions should be drawn.

Similar reductions seen with quarterly dosing in episodic migraine patients§

§With quarterly dosing for episodic migraine patients, reduction in monthly average headache days: 44.4% of patients achieved a ≥50% reduction vs 27.9% with placebo (P<0.001), 25.8% achieved a ≥75% reduction vs 15.4% with placebo (exploratory analysis), and 8.5% achieved 100% reduction vs 4.5% with placebo (exploratory analysis).1,3

What to explore next